Skip to main content

Table 2 Donor and transplant characteristics by ECD status

From: The Canadian experience using the expanded criteria donor classification for allocating deceased donor kidneys for transplantation

  Total N = 1422 ECD n = 325 Non-ECD n = 1097 p value
Donor characteristics     
Age at time of death, years     
 Mean (SD) 47 (14) 63 (6) 42 (12) <0.001
 <50 years 729 (51 %) 0 729 (66 %) <0.001
 50 to 59 years 433 (30 %) 65 (20 %) 368 (34 %)
 ≥60 years 260 (18 %) 260 (80 %) 0
Women 616 (43 %) 152 (47 %) 464 (42 %) 0.153
Body mass index (kg/m2)     
 Mean (SD) 27.2 (5.7) 28.5 (4.9) 26.8 (5.9) <0.001
Pre-terminal serum creatinine, μmol/L     
 Median (Q1–Q3) 66 (53-83) 68 (54-87) 66 (53-82) <0.001
Pre-terminal eGFR, mL/min     
 Median (Q1–Q3) 99 (77–127) 84 (68–110) 102 (81–130) <0.001
Cause of death     
 Cerebrovascular accident 172 (12 %) 71 (22 %) 101 (9 %) <0.001
 Trauma 119 (8 %) 23 (7 %) 96 (9 %)
 Other 1131 (80 %) 231 (71 %) 900 (82 %)
Past medical history     
 Diabetes mellitus 147 (10 %) 68 (21 %) 87 (8 %) <0.001
 Hyperlipidemia 33 (2 %) 11 (3 %) 26 (2 %) 0.147
 Hypertension 518 (36 %) 223 (69 %) 295 (27 %) <0.001
Donation after circulatory death 205 (14) 22 (7 %) 183 (17 %) <0.001
Transplant Characteristics     
Year of transplant     
 2005 150 (11 %) 33 (10 %) 117 (11 %) 0.414
 2006 208 (15 %) 44 (14 %) 164 (15 %)
 2007 241 (17 %) 54 (17 %) 187 (17 %)
 2008 213 (15 %) 52 (16 %) 161 (15 %)
 2009 278 (20 %) 64 (20 %) 214 (20 %)
 2010 266 (19 %) 57 (18 %) 209 (19 %)
 2011 (until March 31) 66 (5 %) 21 (6 %) 45 (4 %)
HLA mismatch (max 6)     
 0 16 (1 %) ≤5 16 (1 %) 0.269
 1 32 (2 %) 9 (3 %) 23 (2 %)
 2 62 (4 %) 17 (5 %) 45 (4 %)
 3 127 (9 %) 28 (9 %) 99 (9 %)
 4 300 (21 %) 61 (19 %) 239 (22 %)
 5 598 (42 %) 135 (42 %) 463 (42 %)
 6 287 (20 %) 75 (23 %) 212 (19 %)
Pulsatile perfusion pump use 275 (19 %) 111 (34 %) 164 (15 %) <0.001
Cold ischemia time, minutes     
 Median (Q1–Q3) 691 (579–813) 691 (574–772) 691 (580–829) 0.098
  1. Cells with ≤5 observations were suppressed to prevent indirect identification of individuals
  2. HLA human leukocyte antigen